Recent advances in methodologies for the discovery of antimycobacterial drugs

Current Bioactive Compounds

Volumn 3, Issue 3, 2007, Pages 201-208

  Primm, Todd P ^a   Franzblau, Scott G ^b  

^a Sam Houston State University   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Alamar blue; Drug discovery; Green fluorescent protein; Luciferase; Mycobacterium; Nitrate reductase; Resazurin

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ANTIINFECTIVE AGENT; MALACHITE GREEN; METRONIDAZOLE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRAZOLIUM;

ANALYTIC METHOD; ANTIBIOTIC SENSITIVITY; ASSAY; AUTOMATION; BETA GALACTOSIDASE ASSAY; BROTH DILUTION; DISK DIFFUSION; DRUG DETERMINATION; DRUG SCREENING; FLOW CYTOMETRY; GREEN FLUORESCENT PROTEIN ASSAY; HUMAN; IN VITRO STUDY; LUCIFERASE ASSAY; METHODOLOGY; MICRODILUTION RESAZURIN ASSAY; MICROPLATE ALAMAR BLUE ASSAY; MYCOBACTERIUM AVIUM; MYCOBACTERIUM TUBERCULOSIS; NITRATE REDUCTASE ASSAY; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; RESAZURIN MICROTITER ASSAY; REVIEW; TETRAZOLIUM MICROPLATE ASSAY; TUBERCULOSIS;

EID: 66149120577     PISSN: 15734072     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340707781695550     Document Type: Review

References (100)

1. Global Alliance for TB Drug Development, www.tballiance.org, accessed June 1, 2006.
2. Scientific Blueprint for TB Drug Development (2001) Global Alliance for TB Drug Development.
3. Primm, T. P., Lucero, C. A. and Falkinham, J. O. 3rd. (2004) Health impacts of environmental mycobacteria. Clin. Microbiol. Rev., 17, 98-106.
4. Vaerewijck, M. J., Huys, G., Palomino, J. C., Swings, J. and Portaels, F. (2005) Mycobacteria in drinking water distribution systems, ecology and significance for human health. FEMS Microbiol. Rev., 29, 911-34.
5. Zumla, A. and Grange, J. (2002) Infection and disease caused by environmental mycobacteria. Curr. Opin. Pulm. Med., 8, 166-72.
6. Tomioka, H. (2004) Present status and future prospects of chemotherapeutics for intractable infections due to Mycobacterium avium complex. Curr. Drug Discov. Technol., 1, 255-68.
7. Chitty, S. A. and Ali, J. (2005) Mycobacterium avium complex pulmonary disease in immunocompetent patients. South Med. J., 98, 646-52.
8. Martins, A. B., Matos, E. D. and Lemos, A. C. (2005) Infection with the Mycobacterium avium complex in patients without predisposing conditions, a case report and literature review. Braz. J. Infect. Dis., 9, 173-9.
9. Prince, D. S., Peterson, D. D., Steiner, R. M., Gottlieb, J. E., Scott, R., Israel, H. L., Figueroa, W. G. and Fish, J. E. (1989) Infection with Mycobacterium avium complex in patients without predisposing conditions. N. Engl. J. Med., 321, 863-8.
10. Fernandes, P. B., Hardy, D. J., McDaniel, D., Hanson, C. W. and Swanson, R. N. (1989) In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob. Agents Chemother., 33, 1531-4.
11. Piersimoni, C., Olivieri, A., Benacchio, L. and Scarparo, C. (2006) Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex, the automated nonradiometric systems. J. Clin. Microbiol., 44, 20-8.
12. Kim, S. J. (2005) Drug-susceptibility testing in tuberculosis, methods and reliability of results. Eur. Respir. J., 25, 564-9.
13. Eichbaum, Q. and Rubin, E. J. (2002) Tuberculosis. Advances in laboratory diagnosis and drug susceptibility testing. Am. J. Clin. Pathol., 118 Suppl, S3-17.
14. Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., 3rd, Tekaia, F., Badcock, K., Basham, D., Brown, D., Chillingworth, T., Connor, R., Davies, R., Devlin, K., Feltwell, T., Gentles, S., Hamlin, N., Holroyd, S., Hornsby, T., Jagels, K., Krogh, A., McLean, J., Moule, S., Murphy, L., Oliver, K., Osborne, J., Quail, M. A., Rajandream, M. A., Rogers, J., Rutter, S., Seeger, K., Skelton, J., Squares, R., Squares, S., Sulston, J. E., Taylor, K., Whitehead, S. and Barrell, B. G. (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature, 393, 537-44.
15. Manca, C., Tsenova, L., Barry, C. E., 3rd, Bergtold, A., Freeman, S., Haslett, P. A., Musser, J. M., Freedman, V. H. and Kaplan, G. (1999) Mycobacterium tuberculosis CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates. J. Immunol., 162, 6740-6.
16. Gruppo, V., Johnson, C. M., Marietta, K. S., Scherman, H., Zink, E. E., Crick, D. C., Adams, L. B., Orme, I. M. and Lenaerts, A. J. (2006) Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 50, 1245-50.
17. Andries, K., Verhasselt, P., Guillemont, J., Gohlmann, H. W., Neefs, J. M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., Williams, P., de Chaffoy, D., Huitric, E., Hoffner, S., Cambau, E., Truffot-Pernot, C., Lounis, N. and Jarlier, V. (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 307, 223-7.
18. Pasca, M. R., Guglierame, P., De Rossi, E., Zara, F. and Riccardi, G. (2005) mmpL7 gene of Mycobacterium tuberculosis is responsible for isoniazid efflux in Mycobacterium smegmatis. Antimicrob. Agents Chemother., 49, 4775-7.
19. Tran, T., Saheba, E., Arcerio, A. V., Chavez, V., Li, Q. Y., Martinez, L. E. and Primm, T. P. (2004) Quinones as antimycobacterial agents. Bioorg. Med. Chem., 12, 4809-13.
20. Zhang, Y., Scorpio, A., Nikaido, H. and Sun, Z. (1999) Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Bacteriol., 181, 2044-9.
21. Brosch, R., Philipp, W. J., Stavropoulos, E., Colston, M. J., Cole, S. T. and Gordon, S. V. (1999) Genomic analysis reveals variation between Mycobacterium tuberculosis H37Rv and the attenuated M. tuberculosis H37Ra strain. Infect. Immun., 67, 5768-74.
22. Mostowy, S., Cleto, C., Sherman, D. R. and Behr, M. A. (2004) The Mycobacterium tuberculosis complex transcriptome of attenuation. Tuberculosis (Edinb), 84, 197-204.
23. Collins, L. and Franzblau, S. G. (1997) Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob. Agents Chemother., 41, 1004-9.
24. Sarmento, A. M. and Appelberg, R. (1995) Relationship between virulence of Mycobacterium avium strains and induction of tumor necrosis factor alpha production in infected mice and in in vitro-cultured mouse macrophages. Infect. Immun., 63, 3759-64.
25. Pedrosa, J., Florido, M., Kunze, Z. M., Castro, A. G., Portaels, F., McFadden, J., Silva, M. T. and Appelberg, R. (1994) Characterization of the virulence of Mycobacterium avium complex (MAC) isolates in mice. Clin. Exp. Immunol., 98, 210-6.
26. Franzblau, S. G., Witzig, R. S., McLaughlin, J. C., Torres, P., Madico, G., Hernandez, A., Degnan, M. T., Cook, M. B., Quenzer, V. K., Ferguson, R. M. and Gilman, R. H. (1998) Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J. Clin. Microbiol., 36, 362-6.
27. Vanitha, J. D. and Paramasivan, C. N. (2004) Evaluation of microplate Alamar blue assay for drug susceptibility testing of Mycobacterium avium complex isolates. Diagn. Microbiol. Infect. Dis., 49, 179-82.
28. De Souza, A. O., Santos Junior, R. R., Melo, P. S., Alderete, J. B., De Conti, R., Haun, M., Sato, D. N. and Duran, N. (2001) Antimycobacterial activity of 4′-bromo-[1, 1′-biphenyl]-4-yl 4-x-phenylmethanone derivatives, and their acute toxicity and cytotoxicity. Pharmazie, 56, 871-4.
29. Franzblau, S. (2000) A rapid, microplate-based assay for evaluating the activity of drugs against Mycobacterium leprae, employing the reduction of Alamar Blue. Lepr. Rev., 71 Suppl, S74-5; discussion S76.
30. Farnia, P., Mohammadi, F., Mirsaedi, M., Zia Zarifi, A., Tabatabee, J., Bahadori, M., Akbar Velayati, A. and Reza Masjedi, M. (2004) Bacteriological follow-up of pulmonary tuberculosis treatment, a study with a simple colorimetric assay. Microbes Infect., 6, 972-6.
31. Farnia, P., Mohammadi, F., Mirsaedi, M., Zarife, A. Z., Tabatabee, J., Bahadori, K., Bahadori, M., Masjedi, M. R. and Velayati, A. A. (2004) Application of oxidation-reduction assay for monitoring treatment of patients with pulmonary tuberculosis. J. Clin. Microbiol., 42, 3324-5.
32. Collins, L. A., Torrero, M. N. and Franzblau, S. G. (1998) Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 42, 344-7.
33. Luna-Herrera, J., Martinez-Cabrera, G., Parra-Maldonado, R., Enciso-Moreno, J. A., Torres-Lopez, J., Quesada-Pascual, F., Delgadillo-Polanco, R. and Franzblau, S. G. (2003) Use of receiver operating characteristic curves to assess the performance of a microdilution assay for determination of drug susceptibility of clinical isolates of Mycobacterium tuberculosis. Eur. J. Clin. Microbiol. Infect. Dis., 22, 21-7.
34. Porras, T. B., Leon, C. I., Guerrero, M. I., Martin, A., Portaels, F. and Palomino, J. C. (2005) (Phenotypic and genotypic methods for detecting multidrug resistance in Mycobacterium tuberculosis). Biomedica, 25, 22-33.
35. Kansal, R. G., Gomez-Flores, R. and Mehta, R. T. (1998) Change in colony morphology influences the virulence as well as the biochemical properties of the Mycobacterium avium complex. Microb. Pathog., 25, 203-14.
36. O'Brien, J., Wilson, I., Orton, T. and Pognan, F. (2000) Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur. J. Biochem., 267, 5421-6.
37. Martin, A., Camacho, M., Portaels, F. and Palomino, J. C. (2003) Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs, rapid, simple, and inexpensive method. Antimicrob. Agents Chemother., 47, 3616-9.
38. Montoro, E., Lemus, D., Echemendia, M., Martin, A., Portaels, F. and Palomino, J. C. (2005) Comparative evaluation of the nitrate reduction assay, the MTT test, and the resazurin microtitre assay for drug susceptibility testing of clinical isolates of Mycobacterium tuberculosis. J. Antimicrob. Chemother., 55, 500-5.
39. Palomino, J. C., Martin, A., Camacho, M., Guerra, H., Swings, J. and Portaels, F. (2002) Resazurin microtiter assay plate, simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 46, 2720-2.
40. De Logu, A., Uda, P., Pellerano, M. L., Pusceddu, M. C., Saddi, B. and Schivo, M. L. (2001) Comparison of two rapid colorimetric methods for determining resistance of Mycobacterium tuberculosis to rifampin, isoniazid, and streptomycin in liquid medium. Eur. J. Clin. Microbiol. Infect. Dis., 20, 33-9.
41. Caviedes, L., Delgado, J. and Gilman, R. H. (2002) Tetrazolium microplate assay as a rapid and inexpensive colorimetric method for determination of antibiotic susceptibility of Mycobacterium tuberculosis. J. Clin. Microbiol., 40, 1873-4.
42. De Logu, A., Borgna, R., Uda, P., Sanna, A., Pellerano, M. L. and Saddi, B. (2003) The 2, 3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxani lide (XTT) assay as rapid colorimetric method for determination of antibiotic susceptibility of clinical Mycobacterium tuberculosis isolates in liquid medium. Clin. Lab., 49, 357-65.
43. De Logu, A., Pellerano, M. L., Sanna, A., Pusceddu, M. C., Uda, P. and Saddi, B. (2003) Comparison of the susceptibility testing of clinical isolates of Mycobacterium tuberculosis by the XTT colorimetric method and the NCCLS standards method. Int. J. Antimicrob. Agents, 21, 244-50.
44. Archuleta, R. J., Yvonne Hoppes, P. and Primm, T. P. (2005) Mycobacterium avium enters a state of metabolic dormancy in response to starvation. Tuberculosis (Edinb), 85, 147-58.
45. Cambau, E., Wichlacz, C., Truffot-Pernot, C. and Jarlier, V. (1999) Evaluation of the new MB redox system for detection of growth of mycobacteria. J. Clin. Microbiol., 37, 2013-5.
46. Heifets, L., Linder, T., Sanchez, T., Spencer, D. and Brennan, J. (2000) Two liquid medium systems, mycobacteria growth indicator tube and MB redox tube, for Mycobacterium tuberculosis isolation from sputum specimens. J. Clin. Microbiol., 38, 1227-30.
47. Liu, Y. C., Huang, T. S. and Huang, W. K. (1999) Comparison of a nonradiometric liquid-medium method (MB REDOX) with the BACTEC system for growth and identification of mycobacteria in clinical specimens. J. Clin. Microbiol., 37, 4048-50.
48. Srivastava, R., Deb, D. K., Srivastava, K. K., Locht, C. and Srivastava, B. S. (1998) Green fluorescent protein as a reporter in rapid screening of antituberculosis compounds in vitro and in macrophages. Biochem. Biophys. Res. Commun., 253, 431-6.
49. Changsen, C., Franzblau, S. G. and Palittapongarnpim, P. (2003) Improved green fluorescent protein reporter gene-based microplate screening for antituberculosis compounds by utilizing an acetamidase promoter. Antimicrob. Agents Chemother., 47, 3682-7.
50. Raghunand, T. R., Bishai, W. R. and Chen, P. (2006) Towards establishing a method to screen for inhibitors of essential genes in mycobacteria, evaluation of the acetamidase promoter. Int. J. Antimicrob. Agents, 28, 36-41.
51. Shawar, R. M., Humble, D. J., Van Dalfsen, J. M., Stover, C. K., Hickey, M. J., Steele, S., Mitscher, L. A. and Baker, W. (1997) Rapid screening of natural products for antimycobacterial activity by using luciferase-expressing strains of Mycobacterium bovis BCG and Mycobacterium intracellulare. Antimicrob. Agents Chemother., 41, 570-4.
52. Arain, T. M., Resconi, A. E., Hickey, M. J. and Stover, C. K. (1996) Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery. Antimicrob. Agents Chemother., 40, 1536-41.
53. Sasahara, K. C., Gray, M. J., Shin, S. J. and Boor, K. J. (2004) Detection of viable Mycobacterium avium subsp. paratuberculosis using luciferase reporter systems. Foodborne Pathog. Dis., 1 , 258-66.
54. Deb, D. K., Srivastava, K. K., Srivastava, R. and Srivastava, B. S. (2000) Bioluminescent Mycobacterium aurum expressing firefly luciferase for rapid and high throughput screening of antimycobacterial drugs in vitro and in infected macrophages. Biochem. Biophys. Res. Commun., 279, 457-61.
55. Roberts, E. A., Clark, A. and Friedman, R. L. (2005) Bacterial luciferase is naturally destabilized in Mycobacterium tuberculosis and can be used to monitor changes in gene expression. FEMS Microbiol. Lett., 243, 243-9.
56. Cho, S. H., Warit, S., Wan, B., Hwang, C. H., Pauli, G. F. and Franzblau, S. G. (2007) Low-Oxygen-Recovery Assay for High-Throughput Screening of Compounds against Nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 51, 1380-5.
57. Jayaprakash, S., Iso, Y., Wan, B., Franzblau, S. G. and Kozikowski, A. P. (2006) Design, Synthesis, and SAR Studies of Mefloquine-Based Ligands as Potential Antituberculosis Agents. Chem. Med. Chem., 1, 593-597.
58. Srivastava, R., Kumar, D. and Srivastava, B. S. (1997) Recombinant Mycobacterium aurum expressing Escherichia coli beta-galactosidase in high throughput screening of antituberculosis drugs. Biochem. Biophys. Res. Commun., 240, 536-9.
59. Srivastava, R., Kumar, D., Subramaniam, P. and Srivastava, B. S. (1997) beta-Galactosidase reporter system in mycobacteria and its application in rapid antimycobacterial drug screening. Biochem. Biophys. Res. Commun., 235, 602-5.
60. Kumar, D., Srivastava, B. S. and Srivastava, R. (1998) Genetic rearrangements leading to disruption of heterologous gene expression in mycobacteria, an observation with Escherichia coli beta-galactosidase in Mycobacterium smegmatis and its implication in vaccine development. Vaccine, 16, 1212-5.
61. Rowland, B., Purkayastha, A., Monserrat, C., Casart, Y., Takiff, H. and McDonough, K. A. (1999) Fluorescence-based detection of lacZ reporter gene expression in intact and viable bacteria including Mycobacterium species. FEMS Microbiol. Lett., 179, 317-25.
62. Witebsky, F. G. and Kruczak-Filipov, P. (1996) Identification of mycobacteria by conventional methods. Clin. Lab. Med., 16, 569-601.
63. Stermann, M., Sedlacek, L., Maass, S. and Bange, F. C. (2004) A promoter mutation causes differential nitrate reductase activity of Mycobacterium tuberculosis and Mycobacterium bovis. J. Bacteriol., 186, 2856-61.
64. Sohaskey, C. D. (2005) Regulation of nitrate reductase activity in Mycobacterium tuberculosis by oxygen and nitric oxide. Microbiology, 151, 3803-10.
65. Shi, L., Sohaskey, C. D., Kana, B. D., Dawes, S., North, R. J., Mizrahi, V. and Gennaro, M. L. (2005) Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration. Proc. Natl. Acad. Sci. USA, 102, 15629-34.
66. Muttucumaru, D. G., Roberts, G., Hinds, J., Stabler, R. A. and Parish, T. (2004) Gene expression profile of Mycobacterium tuberculosis in a non-replicating state. Tuberculosis (Edinb), 84, 239-46.
67. Hutter, B. and Dick, T. (2000) Analysis of the dormancy-inducible narK2 promoter in Mycobacterium bovis BCG. FEMS Microbiol. Lett., 188, 141-6.
68. McCarthy, C. M. (1987) Utilization of nitrate or nitrite as single nitrogen source by Mycobacterium avium. J. Clin. Microbiol., 25, 263-7.
69. Chen, T., Tong, A. and Zhou, Y. (2007) 2-Amino-5, 7-dimethyl-1, 8-naphthyridine as a fluorescent reagent for the determination of nitrite. Spectrochim. Acta A Mol. Biomol. Spectrosc., 66, 586-9.
70. Li, M., Wang, H., Zhang, X. and Zhang, H. S. (2004) Development of a new fluorescent probe, 1, 3, 5, 7-tetramethyl-8-(4′-aminophenyl)-4, 4-difluoro-4-bora-3a, 4a-diaza-s-i ndacence for the determination of trace nitrite. Spectrochim. Acta A Mol. Biomol. Spectrosc., 60, 987-93.
71. Martin, A., Palomino, J. C. and Portaels, F. (2005) Rapid detection of ofloxacin resistance in Mycobacterium tuberculosis by two low-cost colorimetric methods, resazurin and nitrate reductase assays. J. Clin. Microbiol., 43, 1612-6.
72. Kumar, M., Khan, I. A., Verma, V. and Qazi, G. N. (2005) Microplate nitrate reductase assay versus Alamar Blue assay for MIC determination of Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis., 9, 939-41.
73. Coban, A. Y., Birinci, A., Ekinci, B. and Durupinar, B. (2004) Drug susceptibility testing of Mycobacterium tuberculosis with nitrate reductase assay. Int. J. Antimicrob. Agents, 24, 304-6.
74. Kumar, M., Khan, I. A., Verma, V., Kalyan, N. and Qazi, G. N. (2005) Rapid, inexpensive MIC determination of Mycobacterium tuberculosis isolates by using microplate nitrate reductase assay. Diagn. Microbiol. Infect. Dis., 53, 121-4.
75. Rajabi, L., Courreges, C., Montoya, J., Aguilera, R. J. and Primm, T. P. (2005) Acetophenones with selective antimycobacterial activity. Lett. Appl. Microbiol., 40, 212-7.
76. Kontos, F., Maniati, M., Costopoulos, C., Gitti, Z., Nicolaou, S., Petinaki, E., Anagnostou, S., Tselentis, I. and Maniatis, A. N. (2004) Evaluation of the fully automated Bactec MGIT 960 system for the susceptibility testing of Mycobacterium tuberculosis to first-line drugs, a multicenter study. J. Microbiol. Methods, 56, 291-4.
77. Rusch-Gerdes, S., Pfyffer, G. E., Casal, M., Chadwick, M. and Siddiqi, S. (2006) Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J. Clin. Microbiol., 44, 688-92.
78. Ganeswrie, R., Chui, C. S., Balan, S. and Puthucheary, S. D. (2004) Comparison of BACTEC MGIT 960 system and BACTEC 460 TB system for growth and detection of Mycobacteria from clinical specimens. Malays. J. Pathol., 26, 99-103.
79. Bemer, P., Bodmer, T., Munzinger, J., Perrin, M., Vincent, V. and Drugeon, H. (2004) Multicenter evaluation of the MB/BACT system for susceptibility testing of Mycobacterium tuberculosis. J. Clin. Microbiol., 42, 1030-4.
80. Jones, J. J. and Falkinham, J. O., 3rd. (2003) Decolorization of malachite green and crystal violet by waterborne pathogenic mycobacteria. Antimicrob. Agents Chemother., 47, 2323-6.
81. Yamane, N., Chilima, B. Z., Tosaka, M., Okazawa, Y. and Tanno, K. (1996) Determination of antimycobacterial activities of fluoroquinolones against clinical isolates of Mycobacterium tuberculosis, comparative determination with egg-based Ogawa and agar-based Middlebrook 7H10 media. Kekkaku, 71, 453-8.
82. Osato, T. and Shimizu, H. (1972) Studies on early detection of mycobacterial growth by application of STC (2, 3-diphenyl-5-thienyl-(2)-tetrazolium chloride). 3. Study on STC-containing media. Kekkaku, 47, 269-72.
83. Lee, S., Kong, D. H., Yun, S. H., Lee, K. R., Lee, K. P., Franzblau, S. G., Lee, E. Y. and Chang, C. L. (2006) Evaluation of a modified antimycobacterial susceptibility test using Middlebrook 7H10 agar containing 2, 3-diphenyl-5-thienyl-(2)-tetrazolium chloride. J. Microbiol. Methods, 66, 548-51.
84. Pina-Vaz, C., Costa-de-Oliveira, S. and Rodrigues, A. G. (2005) Safe susceptibility testing of Mycobacterium tuberculosis by flow cytometry with the fluorescent nucleic acid stain SYTO 16. J. Med. Microbiol., 54, 77-81.
85. Akselband, Y., Cabral, C., Shapiro, D. S. and McGrath, P. (2005) Rapid mycobacteria drug susceptibility testing using Gel Microdrop (GMD) Growth Assay and flow cytometry. J. Microbiol. Methods, 62, 181-97.
86. Zhang, Y. (2005) The magic bullets and tuberculosis drug targets. Annu. Rev. Pharmacol. Toxicol., 45, 529-64.
87. Wayne, L. G. and Sramek, H. A. (1994) Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 38, 2054-8.
88. Brooks, J. V., Furney, S. K. and Orme, I. M. (1999) Metronidazole therapy in mice infected with tuberculosis. Antimicrob. Agents Chemother., 43, 1285-8.
89. Dhillon, J., Allen, B. W., Hu, Y. M., Coates, A. R. and Mitchison, D. A. (1998) Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int. J. Tuberc. Lung Dis., 2, 736-42.
90. Paramasivan, C. N., Kubendiran, G. and Herbert, D. (1998) Action of metronidazole in combination with isoniazid & rifampicin on persisting organisms in experimental murine tuberculosis. Indian J. Med. Res., 108, 115-9.
91. Wade, M. M. and Zhang, Y. (2004) Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis. J. Med. Microbiol., 53, 769-73.
92. Zhang, Y., Wade, M. M., Scorpio, A., Zhang, H. and Sun, Z. (2003) Mode of action of pyrazinamide, disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J. Antimicrob. Chemother., 52, 790-5.
93. Stover, C. K., Warrener, P., VanDevanter, D. R., Sherman, D. R., Arain, T. M., Langhorne, M. H., Anderson, S. W., Towell, J. A., Yuan, Y., McMurray, D. N., Kreiswirth, B. N., Barry, C. E. and Baker, W. R. (2000) A smallmolecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 405, 962-6.
94. Lenaerts, A. J., Gruppo, V., Marietta, K. S., Johnson, C. M., Driscoll, D. K., Tompkins, N. M., Rose, J. D., Reynolds, R. C. and Orme, I. M. (2005) Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother., 49, 2294-301.
95. Lim, A. and Dick, T. (2001) Plate-based dormancy culture system for Mycobacterium smegmatis and isolation of metronidazole-resistant mutants. FEMS Microbiol. Lett., 200, 215-9.
96. Terwilliger, T. C., Park, M. S., Waldo, G. S., Berendzen, J., Hung, L. W., Kim, C. Y., Smith, C. V., Sacchettini, J. C., Bellinzoni, M., Bossi, R., De Rossi, E., Mattevi, A., Milano, A., Riccardi, G., Rizzi, M., Roberts, M. M., Coker, A. R., Fossati, G., Mascagni, P., Coates, A. R., Wood, S. P., Goulding, C. W., Apostol, M. I., Anderson, D. H., Gill, H. S., Eisenberg, D. S., Taneja, B., Mande, S., Pohl, E., Lamzin, V., Tucker, P., Wilmanns, M., Colovos, C., Meyer-Klaucke, W., Munro, A. W., McLean, K. J., Marshall, K. R., Leys, D., Yang, J. K., Yoon, H. J., Lee, B. I., Lee, M. G., Kwak, J. E., Han, B. W., Lee, J. Y., Baek, S. H., Suh, S. W., Komen, M. M., Arcus, V. L., Baker, E. N., Lott, J. S., Jacobs, W., Jr., Alber, T. and Rupp, B. (2003) The TB structural genomics consortium, a resource for Mycobacterium tuberculosis biology. Tuberculosis (Edinb), 83, 223-49.
97. Kantardjieff, K. and Rupp, B. (2004) Structural bioinformatic approaches to the discovery of new antimycobacterial drugs. Curr. Pharm. Des., 10, 3195-211.
98. Duncan, K. (2004) Identification and validation of novel drug targets in tuberculosis. Curr. Pharm. Des., 10, 3185-94.
99. Okunade, A. L., Elvin-Lewis, M. P. and Lewis, W. H. (2004) Natural antimycobacterial metabolites, current status. Phytochemistry, 65, 1017-32.
100. Pauli, G. F., Case, R. J., Inui, T., Wang, Y., Cho, S., Fischer, N. H. and Franzblau, S. G. (2005) New perspectives on natural products in TB drug research. Life Sci., 78, 485-94.